Effect of Parenteral Support on FibroScan in Short Bowel Syndrome
Trial statusNot yet recruiting
Trial phaseNot listed
Trial typeObservational
Biological sexAll
Age18+
SponsorRigshospitalet, Denmark
About this trial
Home Parenteral Support (HPS) is a life-sustaining treatment for patients with short bowel syndrome and intestinal failure. This study aims to investigate how administration of parenteral support affects FibroScan results in order to determine optimal timing of liver assessment in this patient population.
Eligibility criteria
Qualifiers
Adult patients (≥18 years) with short bowel syndrome with capacity to give consent
Patients receiving regular PS (≥4 days/week and ≥10 liters/week)
Stable clinical condition
Disqualifiers
Known liver cirrhosis
Active infection, severe dehydration, or electrolyte disturbances
Pregnancy
Receiving IV fluids or medications on study day
Trial design
Treatments tested in this trial
- Fibroscan
Treatment groups
20 Participants
are divided into 1 treatment groupLocations
1Department of Digestive Diseases, Transplantation and General Surgery, Rigshospitalet2100, CopenhagenCapital Region, Denmark
Sponsors and collaborators
Rigshospitalet, Denmark
Lead sponsor
Source ClinicalTrials.gov